We are live on ! Find out more
ITP

Iron Triangle Partners Portfolio holdings

AUM $875M
1-Year Est. Return 49.85%
This Fund
S&P 500
This Quarter Est. Return
+16.81%
1 Year Est. Return
+49.85%
3 Year Est. Return
+151.9%
5 Year Est. Return
+239.84%
10 Year Est. Return
–
AUM
$773M
AUM Growth
+$88.7M
Cap. Flow
-$11.4M
Cap. Flow %
-1.47%
Top 10 Hldgs %
55.9%
Holding
33
New
10
Increased
7
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
IDXX icon
Idexx Laboratories
IDXX
+$35.7M
2
SGRY icon
Surgery Partners
SGRY
+$30.3M
3
ILMN icon
Illumina
ILMN
+$26.1M
4
SNY icon
Sanofi
SNY
+$24.4M
5
INSP icon
Inspire Medical Systems
INSP
+$24.3M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$47.6M
2
APLS
Apellis Pharmaceuticals
APLS
+$33.5M
3
DXCM icon
DexCom
DXCM
+$28.2M
4
UHS icon
Universal Health Services
UHS
+$24.2M
5
BSX icon
Boston Scientific
BSX
+$21.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHC icon
1
Acadia Healthcare
ACHC
$2.99B
$61.6M 7.97%
791,993
+26,789
+4% +$1.98M
UHS icon
2
Universal Health Services
UHS
$9.64B
$49.1M 6.35%
321,886
-179,914
-36% -$24.2M
ICLR icon
3
Icon
ICLR
$13B
$48.9M 6.32%
172,675
+42,675
+33% +$11M
ELAN icon
4
Elanco Animal Health
ELAN
$12.7B
$44.7M 5.78%
3,000,000
-412,350
-12% -$4.67M
IDXX icon
5
Idexx Laboratories
IDXX
$43.9B
$42.2M 5.46%
+76,025
New +$35.7M
ISRG icon
6
Intuitive Surgical
ISRG
$128B
$40.5M 5.24%
120,000
-22,000
-15% -$6.56M
ABBV icon
7
AbbVie
ABBV
$454B
$38.7M 5.01%
250,000
– –
MCK icon
8
McKesson
MCK
$99.5B
$37M 4.79%
80,000
+10,000
+14% +$4.55M
DXCM icon
9
DexCom
DXCM
$28.3B
$36M 4.66%
290,000
-275,753
-49% -$28.2M
SGRY icon
10
Surgery Partners
SGRY
$1.98B
$33.4M 4.32%
+1,044,530
New +$30.3M
BRKR icon
11
Bruker
BRKR
$9.14B
$33.1M 4.28%
450,000
+19,157
+4% +$1.23M
ILMN icon
12
Illumina
ILMN
$28.7B
$30.6M 3.96%
+226,160
New +$26.1M
INSP icon
13
Inspire Medical Systems
INSP
$1.47B
$30.5M 3.95%
+150,000
New +$24.3M
BKD icon
14
Brookdale Senior Living
BKD
$3.69B
$28.3M 3.66%
4,859,607
+623,479
+15% +$2.93M
TXG icon
15
10x Genomics
TXG
$5.83B
$26.8M 3.47%
479,374
-187,571
-28% -$8.16M
SNY icon
16
Sanofi
SNY
$105B
$24.9M 3.22%
+500,000
New +$24.4M
LEGN icon
17
Legend Biotech
LEGN
$3.73B
$22.9M 2.96%
380,000
-72,629
-16% -$4.6M
GKOS icon
18
Glaukos
GKOS
$8.92B
$19.4M 2.52%
244,606
-185,394
-43% -$12.6M
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$11.6B
$19.3M 2.5%
+200,000
New +$17.7M
OSCR icon
20
Oscar Health
OSCR
$8.54B
$18.8M 2.43%
+2,052,551
New +$14.2M
PACB icon
21
Pacific Biosciences
PACB
$422M
$18.1M 2.34%
1,843,278
+43,278
+2% +$354K
SDGR icon
22
Schrodinger
SDGR
$1.14B
$16.8M 2.17%
+468,585
New +$13.6M
RGEN icon
23
Repligen
RGEN
$7.39B
$14.8M 1.92%
+82,537
New +$12.8M
MASS icon
24
908 Devices
MASS
$293M
$14.4M 1.87%
1,284,947
+304,484
+31% +$2.08M
TEVA icon
25
Teva Pharmaceuticals
TEVA
$36.2B
$13.6M 1.76%
+1,300,000
New +$12.1M
1
2

Similar funds

8KM
8 Knots Management Dallas, Texas $868M AUM 30.97% 1-Year Est. Return
MFG
MidWestOne Financial Group Iowa City, Iowa $900M AUM 23.95% 1-Year Est. Return
NP
Ninepoint Partners Toronto, Ontario, Canada $904M AUM 39.64% 1-Year Est. Return
GGI
Galaxy Group Investments New York $843M AUM 47.48% 1-Year Est. Return
WFAL
Wedbush Fund Advisers, LLC Pasadena, California $967M AUM
OBWP
O'Brien Wealth Partners Waltham, Massachusetts $756M AUM 13.93% 1-Year Est. Return
TWM
Tolleson Wealth Management Dallas, Texas $693M AUM 17.6% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

Iron Triangle Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Iron Triangle Partners held 33 positions worth $773M, up 13% from $684M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Iron Triangle Partners's Q4 2023 filing shows 10 new, 7 increased, 8 reduced and 7 closed positions. Its largest new stake was Idexx Laboratories: 76,025 shares worth $42.2M. The largest sale was United Therapeutics, an estimated $47.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Iron Triangle Partners's largest Q4 2023 buy was Idexx Laboratories: 76,025 shares worth $42.2M.
  • Iron Triangle Partners added most to Icon in Q4 2023, an estimated $11M increase.
  • Iron Triangle Partners's biggest Q4 2023 reduction was DexCom, cutting an estimated $28.2M.
  • Iron Triangle Partners fully exited United Therapeutics in Q4 2023, selling an estimated $47.6M.
  • Iron Triangle Partners's ten largest holdings make up 56% of its $773M portfolio in Q4 2023.
  • Iron Triangle Partners opened 10 new positions and closed 7 in Q4 2023.
  • Iron Triangle Partners's portfolio value rose 13% quarter-over-quarter to $773M.

Based on Iron Triangle Partners's 13F filing for Q4 2023, filed 14 Feb 2024.